Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 32 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06643117Phase 3
• A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint InhibitorsActive, not recruitingNCT06630429
• Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer PatientsCompletedNCT06629714
• A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT06624059Phase 3
• A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06623136Phase 2
• Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine TumorsCompletedNCT06621147
• A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line TreatmentsCompletedNCT06617390
• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerSuspendedNCT06616623Phase 1
• Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLCCompletedNCT06613633
• CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]CompletedNCT06607393
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2
• A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D MutationTerminatedNCT06599502Phase 1
• Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung CancerCompletedNCT06595498Not applicable
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Phase 1
• CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]CompletedNCT06585189
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1Active, not recruitingNCT06579196Phase 1/2
• Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)Active, not recruitingNCT06577792Not applicable
• A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)CompletedNCT06575933Phase 1
• Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLCActive, not recruitingNCT06569420Phase 3
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesActive, not recruitingNCT06564844Phase 3
• A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationTerminatedNCT06560645Phase 1
• LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06558799Phase 2
• Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of TreatmentCompletedNCT06557967
• Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLCActive, not recruitingNCT06557187Not applicable
• Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerWithdrawnNCT06555263Phase 2
• Pre-operative Tumor Treating Fields in Patients With Resectable Lung CancerWithdrawnNCT06552000Not applicable
• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsActive, not recruitingNCT06544655Phase 1
• An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedNCT06542731Phase 1
• Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung CancerActive, not recruitingNCT06540950Phase 2
• Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC PatientsActive, not recruitingNCT06538038
• A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerCompletedNCT06532032Phase 1/2
• Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerCompletedNCT06525246Phase 1
• Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)Active, not recruitingNCT06524427Not applicable
• Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)WithdrawnNCT06522360Phase 2
• First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung CancerCompletedNCT06521034Phase 1/2
• Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung CancerActive, not recruitingNCT06518018
• Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid SizeCompletedNCT06516796
• Exercise as Maintenance Therapy in Advanced Lung CancerTerminatedNCT06513663Not applicable
• Prognostic Significance of the Uncertain Resection in NSCLCActive, not recruitingNCT06511661
• A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsTerminatedNCT06507891Phase 1/2
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain MetastasisCompletedNCT06501378Phase 2
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainActive, not recruitingNCT06500455Phase 3
• A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT06498986Phase 2
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06497556Phase 3
• Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT06494241
• A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06487156
• ETERNALS: Remote Monitoring in Lung Cancer PatientsStatus unknownNCT06479005Not applicable
• The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung CancerCompletedNCT06477055
• A Study of DM001 in Patients With Advanced Solid TumorsActive, not recruitingNCT06475937Phase 1
• A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingNCT06472076Phase 3
• A Study of SGN-MesoC2 in Advanced Solid TumorsTerminatedNCT06466187Phase 1
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06465329Phase 2
• Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot StudyActive, not recruitingNCT06461338Not applicable
• Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer TreatmentsCompletedNCT06448793
• Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingNCT06448754Phase 2
• A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationTerminatedNCT06448364Phase 1
• A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Phase 3
• A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Active, not recruitingNCT06447662Phase 1
• A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLCActive, not recruitingNCT06443684
• TGRX-326 Pharmacokinetic Mass BalanceCompletedNCT06438367Phase 1
• An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung CancerWithdrawnNCT06427369Phase 1
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06417814Phase 3
• A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal MetastasisActive, not recruitingNCT06410040
• A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung CancerCompletedNCT06405815
• Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2
• JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingNCT06391944Phase 2
• A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Active, not recruitingNCT06382129Phase 3
• A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)Active, not recruitingNCT06382116Phase 3
• A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsCompletedNCT06378658Phase 1
• Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT06376084
• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsTerminatedNCT06364696Phase 1
• A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06360211Phase 1
• A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy ParticipantsCompletedNCT06348888Phase 1
• A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT06348199Phase 3
• Alectinib-induced Endocrine ToxicityCompletedNCT06339554
• High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)Active, not recruitingNCT06337552Not applicable
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsTerminatedNCT06336148Phase 1
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingNCT06333951Phase 1
• A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06333678Phase 2
• An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLCWithdrawnNCT06332300Phase 2
• Effects of Immune Checkpoint Inhibitors on Coronary MicrovasculatureActive, not recruitingNCT06332131
• Radiomics and Radiogenomics of Non-small Cell Lung CancerCompletedNCT06331975Not applicable
• Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After ImmunotherapyWithdrawnNCT06331585Phase 2
• A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06329895Phase 1
• Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)Active, not recruitingNCT06322108Phase 2
• Safety of Effivia®, a Bevacizumab BiosimilarCompletedNCT06313268
• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Phase 3
• TGRX-326 Pharmacokinetic Food Effect Bioavailability StudyCompletedNCT06304805Phase 1
• Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLCActive, not recruitingNCT06300424Phase 2
• A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)CompletedNCT06295432Phase 2
• TGRX-326 Pharmacokinetic Drug InteractionCompletedNCT06294561Phase 1
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayTerminatedNCT06287463Phase 1
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesActive, not recruitingNCT06282874Phase 4
• A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCTerminatedNCT06280196Phase 3
• Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.Active, not recruitingNCT06277388

← Carcinoma, Non-Small-Cell Lung overview